Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases by Janna J.A. O. Schoenmaekers, MD, Jeroen Bruinsma, PhD, Claire Wolfs, PhD, Lidia Barberio, MSc, Anita Brouns, MD, Anne-Marie C. Dingemans, MD, PhD, Lizza E.L. Hendriks, MD, PhD

Get full text

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands by Anneloes L. Noordhof, MD, Esther M. Swart, MSc, Ronald A.M. Damhuis, PhD, Lizza E.L. Hendriks, MD, PhD, Peter W.A. Kunst, MD, PhD, Mieke J. Aarts, PhD, Wouter H. van Geffen, MD, PhD

Get full text

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC by M. Jebbink, MD, A.J. de Langen, MD, PhD, K. Monkhorst, MD, PhD, M.C. Boelens, PhD, D. van den Broek, PhD, V. van der Noort, PhD, C.J. de Gooijer, MD, PhD, M. Mahn, MSc, A.J. van der Wekken, MD, PhD, L. Hendriks, MD, PhD, S.M.S. Hashemi, MD, PhD, M.S. Paats, MD, PhD, A.C. Dingemans, MD, PhD, E.F. Smit, MD, PhD

Get full text

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC by Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD

Get full text